PART I Background Matinas BioPharma Holdings, Inc. (Matinas or the Company) is a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using our lipid nanocrystal (LNC) platform delivery technology (the LNC Platform). Our lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fung...
Q2 FY2026 — expected 2026-08-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001493152-26-014132 | EDGAR | 78K words |
| 2025-04-15 | 2024-12-31 | 0001641172-25-004882 | EDGAR | — |
| 2024-03-27 | 2023-12-31 | 0001493152-24-011493 | EDGAR | — |
| 2023-03-15 | 2022-12-31 | 0001493152-23-007726 | EDGAR | — |
| 2022-03-08 | 2021-12-31 | 0001493152-22-006231 | EDGAR | — |
| 2021-03-29 | 2020-12-31 | 0001493152-21-006979 | EDGAR | — |
| 2020-03-09 | 2019-12-31 | 0001493152-20-003558 | EDGAR | — |
| 2019-04-01 | 2018-12-31 | 0001493152-19-004560 | EDGAR | — |
| 2018-03-16 | 2017-12-31 | 0001493152-18-003518 | EDGAR | — |
| 2017-03-31 | 2016-12-31 | 0001144204-17-018184 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001493152-25-021506 | EDGAR | 17K words |
| 2025-08-14 | 2025-06-30 | 0001641172-25-024014 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001641172-25-011026 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001493152-24-045201 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001493152-24-032144 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001493152-24-018417 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001493152-23-039892 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001493152-23-027340 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0001493152-23-016151 | EDGAR | — |
| 2022-11-02 | 2022-09-30 | 0001493152-22-030195 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001493152-22-021955 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001493152-22-012915 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-03 | 0001493152-26-015170 | EDGAR | 1K words |
| 2026-01-23 | 0001493152-26-003445 | EDGAR | — |
| 2025-12-12 | 0001493152-25-027529 | EDGAR | — |
| 2025-11-21 | 0001493152-25-024691 | EDGAR | — |
| 2025-08-18 | 0001641172-25-024520 | EDGAR | — |
| 2025-08-06 | 0001641172-25-022445 | EDGAR | — |
| 2025-06-23 | 0001641172-25-016064 | EDGAR | — |
| 2025-05-02 | 0001641172-25-008417 | EDGAR | — |
| 2025-04-08 | 0001641172-25-003271 | EDGAR | — |
| 2025-04-04 | 0001641172-25-002818 | EDGAR | — |
219 total filings indexed. 187 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001582554 |
| Ticker | MTNB |
| Exchange | NYSE |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.matinasbiopharma.com |
| Listed | 2014-07-21 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report